First filing for Takeda's once-weekly DPP-4 inhibitor but prospects limited?
This article was originally published in Scrip
Takeda has made the first approval filing for its once-weekly DPP-4 inhibitor trelagliptin (SYR-472), in Japan for the treatment of type 2 diabetes, although some analysts are cautious over its sales prospects despite the apparent convenience benefits.
You may also be interested in...
Highly promising results for a novel, easy to use form of CAR therapy, as early trial in hematologic malignancies shows a high response and low toxicity.
Reimbursement issues continued to dominate the policy sphere in Japan during the last decade, while new forms of therapy benefited from positive regulatory reforms. Meanwhile, consolidation and specialization were major threads running through the corporate sector.
Spreading China outbreak not a point of focus for companies or analysts in quarterly results briefings.